Thyroid Cancer- Pipeline Insight, 2024

Thyroid Cancer- Pipeline Insight, 2024

DelveInsight’s, “Thyroid Cancer- Pipeline Insight, 2024,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Thyroid Cancer Understanding

Thyroid Cancer: Overview

Thyroid cancer starts in the cells that make up your thyroid gland. The thyroid gland makes hormones that help control many processes in your body. Thyroid cancer is relatively common enough so that all of us will know somebody with thyroid cancer. There are more than 50,000 new cases of thyroid cancer each year in the United States. Women are more likely to develop thyroid cancer at a ratio of three to one. Thyroid cancer can occur in any age group, although it is most common after age 30 and its aggressiveness increases significantly in patients above 55 years of age. Thus, most people with thyroid cancer are women over age 30. The majority of patients present with a nodule on their thyroid which typically does not cause symptoms. Remember, likely over 90% of thyroid nodules are not cancer. But, when a thyroid cancer does begin to grow within a thyroid gland, it almost always does so within a discrete nodule within the thyroid. Said differently, the entire thyroid isn’t a cancer; the cancer grows from within a nodule which is within the thyroid. It’s normal to have few or no symptoms early on. One of the most common symptoms is a lump (growth) called a nodule in the neck. This might be found during a routine physical. Most thyroid nodules are not cancer. A biopsy is the only way to know for sure that you have thyroid cancer. Small pieces of tissue are taken from the thyroid and tested for cancer. The treatment choices depends on the type of thyroid cancer person have, test results, the stage of the cancer, and the overall health. Most thyroid cancers are slow to grow and spread (metastasize). But some kinds can grow and spread quickly.

""Thyroid Cancer- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Thyroid Cancer pipeline landscape is provided which includes the disease overview and Thyroid Cancer treatment guidelines. The assessment part of the report embraces, in depth Thyroid Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Thyroid Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Thyroid Cancer.

Thyroid Cancer Emerging Drugs Chapters

This segment of the Thyroid Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Thyroid Cancer Emerging Drugs

• Donafenib: Suzhou Zelgen Biopharmaceuticals

Donafenib, an orally administered multikinase inhibitor, is being developed by Suzhou Zelgen Biopharmaceuticals for the treatment of Late stage cancers. The product targets Raf kinase and various receptor tyrosine kinases (RTKs), with potential antineoplastic activity. Currently, it is in phase 3 of development stage for the treatment of thyroid cancer.

• Anlotinib: Jiangsu Chia-Tai Tianqing Pharmaceutical

Anlotinib is an orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. Currently, it is in phase 3 of development stage for the treatment of thyroid cancer.

• Nivolumab: Bristol-Myers Squibb

Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. Currently, it is in phase 2 of development stage for the treatment of thyroid cancer.

• RX208: Suzhou NeuPharma

RX108 is a novel small-molecule inhibitor of sodium-potassium adenosine triphosphatase (Na+/K+-ATPase). Na+/K+-ATPase is an ion carrier protein and controls transportation of Na+ and K+ across the cell membrane. Studies have shown that Na+/K+-ATPase serves as a scaffold for the assembly of multiple-protein signaling complex and plays an important role in the regulation of cell growth, motility, and proliferation beyond that of ion transport. Expression of Na+/K+-ATPase is elevated in various tumors. Inhibition of Na+/K+-ATPase in cancer cells triggers a series of downstream signaling activities that lead to cell-cycle arrest, apoptosis and autophagic cell death. Targeting Na+/K+-ATPase offers a potential new approach for the development of novel anti-cancer therapies.

• AIC100: AffyImmune Therapeutics

AffyImmune’s lead product, AIC100, is an affinity-tuned, ICAM-1 targeted, third generation CAR T cell therapy. AIC100’s CAR has an affinity to ICAM-1 similar to the affinity between naturally-occurring T cells and their targets, which is much lower than most CARs used to date and reduces on-target off-tumor toxicities. AIC100 also expresses SSTR2 for real-time monitoring of CAR T cell distribution and activity.Preclinical studies demonstrate that AIC100 induces robust and enduring tumor eradication without toxicity-related relapse or fatality in various solid tumor models. Studies also suggest the potential for combination with anti-PD-1 therapies. AffyImmune is currently enrolling patients in our Phase I trial for ARTC.

Further product details are provided in the report……..

Thyroid Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Thyroid Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Thyroid Cancer

There are approx. 40+ key companies which are developing the therapies for Thyroid Cancer. The companies which have their Thyroid Cancer drug candidates in the most advanced stage, i.e. phase III include, Suzhou Zelgen Biopharmaceuticals

• Phases

DelveInsight’s report covers around 40+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Thyroid Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Thyroid Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Thyroid Cancer drugs.

Thyroid Cancer Report Insights

• Thyroid Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Thyroid Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Thyroid Cancer drugs?
• How many Thyroid Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Thyroid Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Thyroid Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Thyroid Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Suzhou Zelgen Biopharmaceuticals
• Jiangsu Chia-Tai Tianqing Pharmaceutical
• Takeda
• Bristol-Myers Squibb
• Genentech
• AffyImmune Therapeutics, Inc.
• Taizhou Hanzhong biomedical co. LTD
• NantCell, Inc.
• Bayer
• Merck Sharp & Dohme Corp.
• Pfizer
• MedImmune LLC
• Eisai Inc.
• cCAM Biotherapeutics
• Purple Biotech Ltd.
• Turning Point Therapeutics, Inc.
• Hoffmann-La Roche
• Bicara Therapeutics
• Novartis
• GlobeImmune
• GE Healthcare
• IBC Pharmaceuticals
• Debiopharm
• Blueprint Medicines
• Ono Pharmaceutical
• Array BioPharma
• Celldex Therapeutics Inc
• VBL Therapeutics
• Biovista

Key Products

• RX208
• Donfenib
• Anlotinib
• Nivolumab
• AIC100
• GI-6207
• Ipilimumab
• MLN0128
• Pembrolizumab
• SU011248